Panacea Biotec Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.0 pts less than Nifty Microcap 250 and 4.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Panacea Biotec has filed its financial results for the quarter and year ended March 31, 2025 with NSE, as required under listing regulations. This is a standard regulatory disclosure indicating the timely submission of audited results. The actual numbers, including revenue, profit/loss, and margins, are contained in the detailed results document which is not provided here. Investors should review the full results PDF for specifics on revenue growth, profitability, and segment performance. No specific quantitative details can be confirmed from the headline alone.
This filing confirms compliance with listing obligations but does not indicate any extraordinary event. Shareholders should look at the detailed results to assess performance trends and any forward-looking commentary from management.